{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:21:20Z","timestamp":1778905280632,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Novartis Farmac\u00e9utica S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0517-9","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T12:39:19Z","timestamp":1474893559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial"],"prefix":"10.1186","volume":"11","author":[{"given":"Nicol\u00e1s Roberto","family":"Robles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Peces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"G\u00f3mez-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"\u00c1lvarez-Ossorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"P\u00e9rez-Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Morote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Herrera-Imbroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Carballido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urbano","family":"Anido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Meseguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"issue":"1","key":"517_CR1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","volume":"68","author":"SL Dabora","year":"2001","unstructured":"Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64\u201380.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"517_CR2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","volume":"13","author":"O Sancak","year":"2005","unstructured":"Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005;13(6):731\u201341.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"517_CR3","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1378\/chest.14-3095","volume":"148","author":"AS Kristof","year":"2015","unstructured":"Kristof AS, Li PZ, Major P, Landry JS. Lymphangioleiomyomatosis and Tuberous Sclerosis Complex in Quebec: Prevalence and Health-care Utilization. Chest. 2015;148(2):444\u20139.","journal-title":"Chest"},{"issue":"1","key":"517_CR4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archneur.1994.00540130110018","volume":"51","author":"G Ahlsen","year":"1994","unstructured":"Ahlsen G, Gillberg IC, Lindblom R, Gillberg C. Tuberous sclerosis in Western Sweden. A population study of cases with early childhood onset. Arch Neurol. 1994;51(1):76\u201381.","journal-title":"Arch Neurol"},{"issue":"Spec No. 2","key":"517_CR5","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1093\/hmg\/ddi260","volume":"14","author":"DJ Kwiatkowski","year":"2005","unstructured":"Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet. 2005;14(Spec No. 2):R251\u20138.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"517_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-4632.2010.04727.x","volume":"50","author":"J Borkowska","year":"2011","unstructured":"Borkowska J, Schwartz RA, Kotulska K, Jozwiak S. Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 2011;50(1):13\u201320.","journal-title":"Int J Dermatol"},{"issue":"3","key":"517_CR7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1523-1755.2004.00838.x","volume":"66","author":"JJ Bissler","year":"2004","unstructured":"Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int. 2004;66(3):924\u201334.","journal-title":"Kidney Int"},{"issue":"4 Pt 1","key":"517_CR8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0022-5347(05)64440-0","volume":"168","author":"CP Nelson","year":"2002","unstructured":"Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol. 2002;168(4 Pt 1):1315\u201325.","journal-title":"J Urol"},{"issue":"4","key":"517_CR9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255\u201365.","journal-title":"Pediatr Neurol"},{"issue":"12","key":"517_CR10","first-page":"1205","volume":"95","author":"A Levy","year":"2008","unstructured":"Levy A, Sauvin LA, Massard C, Soria JC. Everolimus (RAD001) and solid tumours: a 2008 summary. Bull Cancer. 2008;95(12):1205\u201311.","journal-title":"Bull Cancer"},{"issue":"5","key":"517_CR11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000350625","volume":"36","author":"V Grunwald","year":"2013","unstructured":"Grunwald V, Weikert S, Pavel ME, Horsch D, Luftner D, Janni W, et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie. 2013;36(5):295\u2013302.","journal-title":"Onkologie"},{"key":"517_CR12","unstructured":"European Medicines Agency. Afinitor: Summary of Product Characteristics. European Medicines Agency. 2015. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001038\/WC500022814.pdf . Accessed 08 Feb 2016."},{"issue":"9869","key":"517_CR13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324.","journal-title":"Lancet"},{"issue":"1","key":"517_CR14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfv249","volume":"31","author":"JJ Bissler","year":"2015","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant. 2015;31(1):111\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"9861","key":"517_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332.","journal-title":"Lancet"},{"issue":"6","key":"517_CR16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","volume":"29","author":"JC Kingswood","year":"2014","unstructured":"Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrol Dial Transplant. 2014;29(6):1203\u201310.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"517_CR17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","volume":"80","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80(6):574\u201380.","journal-title":"Neurology"},{"issue":"19","key":"517_CR18","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801\u201311.","journal-title":"N Engl J Med"},{"issue":"5","key":"517_CR19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archneur.57.5.662","volume":"57","author":"MH Hyman","year":"2000","unstructured":"Hyman MH, Whittemore VH. National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol. 2000;57(5):662\u20135.","journal-title":"Arch Neurol"},{"issue":"12","key":"517_CR20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","volume":"13","author":"ES Roach","year":"1998","unstructured":"Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13(12):624\u20138.","journal-title":"J Child Neurol"},{"key":"517_CR21","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Bethesda, USA. 2010. Available from: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf . Accessed 24 Nov 2015."},{"issue":"4","key":"517_CR22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","volume":"66","author":"MJ Eijkemans","year":"2015","unstructured":"Eijkemans MJ, van der Wal W, Reijnders LJ, Roes KC, van Waalwijk van Doorn-Khosrovani SB, Pelletier C, et al. Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands. Am J Kidney Dis. 2015;66(4):638\u201345.","journal-title":"Am J Kidney Dis"},{"key":"517_CR23","doi-asserted-by":"publisher","unstructured":"Budde K, Zonnenberg BA, Frost M, Cheung W, Urva S, Brechenmacher T, et al. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br J Clin Pharmacol. 2015; doi: 10.1111\/bcp.12834","DOI":"10.1111\/bcp.12834"},{"key":"517_CR24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1750-1172-7-87","volume":"7","author":"C Cabrera-Lopez","year":"2012","unstructured":"Cabrera-Lopez C, Marti T, Catala V, Torres F, Mateu S, Ballarin J, et al. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. Orphanet J Rare Dis. 2012;7:87.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T23:42:59Z","timestamp":1498347779000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0517-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0517-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]},"article-number":"128"}}